newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

ALGS
  • Aligos Therapeutics presented positive data from eight posters and one oral presentation at AASLD The Liver Meeting 2025 in Washington, D.C.
  • Pevifoscorvir sodium (ALG-000184) demonstrated sustained suppression of HBV DNA below the lower limit of quantification in 75% of HBeAg+ subjects & 100% of HBeAg- subjects during an 8-week nucleos(t)ide analog follow-up period.
  • Post-treatment data indicated that reductions in HBV antigens & HBV RNA were maintained after transitioning to standard-of-care therapy, suggesting pevifoscorvir sodium reduces the cccDNA pool.
  • Preclinical in vitro data showed the active moiety ALG-001075 prevents cccDNA formation & HBV DNA integration.
  • Complete 96-week monotherapy data revealed 100% of HBeAg+ subjects achieved HBV DNA below the lower limit of quantification, with 50% reaching undetectable levels.
  • All 11 HBeAg- subjects maintained HBV DNA suppression below the lower limit of quantification for 96 weeks, with 89% reaching undetectable levels by Week 96.
  • No viral breakthrough was observed in any subjects receiving pevifoscorvir sodium monotherapy for up to 96 weeks.
  • The company reported favorable tolerability profiles across both HBeAg+ & HBeAg- cohorts receiving 300 mg daily doses.
  • CEO Lawrence Blatt highlighted the first-in-class potential of pevifoscorvir sodium & noted progress in the Phase 2 B-SUPREME study & HBV ASO program.
  • The company presented six additional preclinical posters covering CAM-E mechanisms, lead optimization for HBV ASO, & siRNA molecules for MASH treatment.
  • Presentation details are available on the Aligos website following the live event.